We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


AMRI Announces CFO Transition

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "AMRI Announces CFO Transition"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

AMRI has announced that Michael M. Nolan, senior vice president and chief financial officer, will be departing AMRI. Mr. Nolan will remain with AMRI through February 2015 to support an orderly transition.

The company also announced that Felicia Ladin will join the company in the same role, effective February 4, 2015.

"We appreciate Mike's contributions to AMRI's growth, and I know I speak for the management team and Board of Directors in wishing him success with his future endeavors," said William S. Marth, AMRI's President and Chief Executive Officer.

"I am pleased that Felicia will be joining the AMRI team at this important time for the company," continued Mr. Marth. "As we continue to build and integrate our business, Felicia's strong track record of building global finance infrastructures and teams will be a tremendous addition to AMRI."

Ms. Ladin brings more than 20 years of finance, accounting and tax management experience to AMRI. A CPA by training, Ladin has spent the majority of her career in the pharmaceutical industry, most recently as Senior Vice President, CFO, Global Specialty Medicines at Teva Pharmaceuticals, USA.

Between 2008 and 2014, Ms. Ladin held positions of increasing responsibility directing Teva's financial planning and analysis operations, and from 2002 to 2008 was tax director for the U.S.

During her 12 year tenure at Teva, Ladin was instrumental in developing and implementing financial systems and infrastructure through a number of acquisitions, and driving consistency and efficiencies across locations, supporting the Specialty Medicine division's growth into an $8 billion global business.

The company intends to release its fourth quarter and full year 2014 financial results and 2015 guidance, including the most recent acquisitions, in February 2015.